Publication of ALYCANTE study in Nature Medicine
LYSA-LYSARC announces the publication in Nature Medicine of the ALYCANTE study demonstrating the clinical benefit of CAR-T cells (axicabtagene ciloleucel) as a second-line therapy in transplantineligible patients with large B-cell lymphoma (LBCL).
LYSA-LYSARC cooperative group is proud to announce today the publication in Nature Medicine of the full clinical results of the ALYCANTE study, showing high complete response rates and durable remissions after CAR-T cell therapy in second line for transplant-ineligible patients with relapse/refractory (R/R) LBCL. The partial results were presented at ASH 2022 and the final analysis confirms the excellent results which are highlighted in the publication in the renowned scientific journal Nature Medicine.
Read the press release here: